Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal

Fineline Cube Jan 20, 2026
Company Deals

Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus

Fineline Cube Jan 20, 2026
Company Deals Medical Device

EasyDiagnosis Bio to Acquire 51% of Ailex Medical in $5.1M Deal, Gains IVD Platform

Fineline Cube Jan 20, 2026
Company Deals

AstraZeneca Secures Full Global Rights to AbelZeta’s C‑CAR031 in $630M CAR‑T Deal

Fineline Cube Jan 20, 2026
Company Deals

Medtronic and Precision Neuroscience Form First Brain‑Device Alliance to Access Neural Data

Fineline Cube Jan 20, 2026
Policy / Regulatory

NHSA Releases NRDL Value Assessment Guidelines, Prioritizing 8 Drug Categories for Real‑World Evaluation

Fineline Cube Jan 15, 2026
Company Drug

Ocumension’s OT-703 DME Implant Enrolls 195 Patients in China Real-World Study

Fineline Cube Jan 20, 2026
Company Drug

AIM Vaccine’s PCV20 Gets NMPA Clinical Approval, Challenging Pfizer’s Monopoly

Fineline Cube Jan 20, 2026
Company

Gilead’s 2023 Flat Sales Reflect Stagnation and COVID-19 Demand Decline

Fineline Cube Feb 7, 2024

Gilead Sciences Inc. (NASDAQ: GILD) has reported a stagnant performance for the year 2023, with...

Company

Astellas Pharma Inc. Reports 2.1% YOY Growth in Q1-Q3 Fiscal 2023 Revenues

Fineline Cube Feb 7, 2024

Tokyo-based pharmaceutical company Astellas Pharma Inc., (TYO: 4503) has announced financial results for the first...

Company

Gilead’s 2023 Stagnation Foresees Flat 2024 Sales as Veklury Revenues Dwindle

Fineline Cube Feb 7, 2024

Gilead Sciences (NASDAQ: GILD) has reported a stagnant performance for 2023, with product sales remaining...

Company

Amgen’s Q4 2023 Results Showcase 9% YOY Growth, 18 Drugs Hit Record Sales

Fineline Cube Feb 7, 2024

Biopharmaceutical giant Amgen (NASDAQ: AMGN) has reported its financial results for Q4 2023, announcing annual...

Policy / Regulatory

Medical Institutions Directed to Adhere to ‘Six Should Do’s’ and ‘Six Prohibited Behaviors’ for Academic Lectures

Fineline Cube Feb 7, 2024

Medical institutions have reportedly been circulated with a “Notice on Issuing Work Tips for Medical...

Policy / Regulatory

China Proposes Market-Oriented Pricing for Innovative Drugs to Boost High-Quality Development

Fineline Cube Feb 7, 2024

The National Healthcare Security Administration (NHSA) has unveiled a draft Notification on “Establishing a Price...

Company

Eli Lilly’s 2023 Revenue Soars on Metabolism Drugs, Anticipates Further Growth in 2024

Fineline Cube Feb 7, 2024

Eli Lilly and Company (NYSE: LLY) reported a robust 2023 financial performance with a 20%...

Company Drug

Jiangsu Hengrui Receives NMPA Approval for Phase II Study of GLP-1 Agonist for Weight Loss

Fineline Cube Feb 7, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...

Company

Innovent Biologics Posts 65% YOY Growth in Q4 2023 with Over RMB 1.6 Billion in Sales

Fineline Cube Feb 7, 2024

Chinese biopharmaceutical company Innovent Biologics Inc., (HKG: 1801) has reported impressive quarterly sales figures, announcing...

Company Drug

Shanghai Procurement Platform Offers Price Cut Leeway to Escape ‘High-Priced Drugs’ Tag

Fineline Cube Feb 7, 2024

Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) platform has announced a significant policy shift regarding non-winning...

Company Drug

BioNTech and Duality’s DB-1305 Earns Fast-Track Status for Platinum-Resistant Cancers

Fineline Cube Feb 7, 2024

German biotechnology company BioNTech SE (NASDAQ: BNTC) and its partner Duality Biologics (Suzhou) Co., Ltd...

Policy / Regulatory

NMPA Reports Record 61 Innovative Medical Device Approvals in 2023

Fineline Cube Feb 6, 2024

The National Medical Products Administration (NMPA) has released its 2023 medical device filings work report,...

Company Deals

Novartis to Acquire MorphoSys for €2.7 Billion in Strategic Oncology Expansion

Fineline Cube Feb 6, 2024

Switzerland-based Novartis (NYSE: NVS) has announced a voluntary public takeover offer to acquire Germany-based biopharmaceutical...

Company Deals

Bayer Partners with TetraScience to Enhance Data Management in Product Development

Fineline Cube Feb 6, 2024

Germany-based Bayer (ETR: BAYN) has announced a partnership with data management firm TetraScience to collect...

Company Deals

Zhejiang Anglikang Enters R&D Cooperation Agreement with Affinity Biopharmaceutical

Fineline Cube Feb 6, 2024

China-based Zhejiang Anglikang Pharmaceutical Co., Ltd. (SHE: 002940) has entered into a research and development...

Company Deals

Novo Holdings to Acquire Catalent for $16.5 Billion in Strategic Move to Enhance Biopharmaceutical Capacity

Fineline Cube Feb 6, 2024

Novo Holdings, the principal shareholder of Denmark’s Novo Nordisk (CPH: NOVO-B), has announced a definitive...

Company Drug

MSD’s Keytruda Secures 13th Indication Approval in China for Biliary Carcinoma Treatment

Fineline Cube Feb 6, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK), a leading US pharmaceutical company, has announced that...

Company Medical Device

Peijia Medical’s Taurus Atlas Pro Balloon Dilation Catheter Approved by NMPA for Pulmonary Valve Procedures

Fineline Cube Feb 6, 2024

Peijia Medical Ltd (HKG: 9996) has announced that it has received marketing approval from the...

Company

MicroPort CRM Receives NMPA Approval for Next-Generation MRI-Safe Implantable Cardiac Pacing System

Fineline Cube Feb 6, 2024

MicroPort Scientific Corp. (HKG: 0853), a leading Shanghai-based medical device company, has announced that its...

Company Deals

Jiangsu Wuzhong Pharmaceutical Partners with SPH KDL Health to Boost Aesthetics Product AestheFill

Fineline Cube Feb 6, 2024

Jiangsu Wuzhong Pharmaceutical Group Corp., (SHA: 600200), a leading Chinese pharmaceutical company, has announced a...

Posts pagination

1 … 348 349 350 … 611

Recent updates

  • Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal
  • Ocumension’s OT-703 DME Implant Enrolls 195 Patients in China Real-World Study
  • AIM Vaccine’s PCV20 Gets NMPA Clinical Approval, Challenging Pfizer’s Monopoly
  • Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus
  • Grand Pharmaceutical Files TLX591-CDx PSMA Diagnostic for Prostate Cancer in China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal

Company Drug

Ocumension’s OT-703 DME Implant Enrolls 195 Patients in China Real-World Study

Company Drug

AIM Vaccine’s PCV20 Gets NMPA Clinical Approval, Challenging Pfizer’s Monopoly

Company Deals

Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.